Table 4 Hazard ratios of developing a malignancy
Univariate Cox regression | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
HR | 95% CI | P | adjusted HR | 95% CI | P | |
Characteristics at baseline | ||||||
Age (per 10 yrs increase) | 1.82 | 1.44 to 2.31 | < 0.0001 | 1.71 | 1.35 to 2.17 | < 0.0001 |
Male vs. female | 1.61 | 0.98 to 2.65 | 0.062 | 1.47 | 0.89 to 2.43 | 0.13 |
Co-morbid conditions: | ||||||
COPD | 3.64 | 1.92 to 6.91 | < 0.0001 | 2.63 | 1.37 to 5.04 | 0.004 |
Gastrointestinal disease | 2.19 | 1.20 to 3.98 | 0.010 | 1.81 | 0.99 to 3.30 | 0.0534 |
Renal disease | 1.93 | 0.70 to 5.28 | 0.20 | |||
Characteristics at follow-up | ||||||
DAS28 (per unit increase) | 1.24 | 1.02 to 1.50 | 0.034 | |||
DAS28 | ||||||
< 3.2 | Referent | |||||
3.2 to 5.1 | 1.28 | 0.54 to 3.06 | 0.58 | |||
> 5.1 | 2.00 | 0.82 to 4.86 | 0.13 | |||
Ever exposed to | ||||||
Conventional DMARDs only | Referent | Referent | ||||
Anti-TNF agents | 0.61 | 0.39 to 0.97 | 0.039 | 0.70 | 0.44 to 1.12 | 0.133 |
Anakinra | 1.16 | 0.47 to 2.89 | 0.75 | 1.39 | 0.56 to 3.48 | 0.480 |